Key Takeaways NVO's Phase III evoke studies showed Rybelsus failed to slow AD progression versus placebo.Rybelsus improved AD-related biomarkers but showed no measurable impact on disease progression.Novo Nordisk will halt the extension phase and present top-line data in December with full results in 2026.Novo Nordisk (NVO) reported disappointing top-line data from the two-year primary analysis of two late-stage studies evaluating Rybelsus (oral semaglutide 14 mg) for early-stage symptomatic Alzheimer’s dis ...

Anavex Life Sciences (NasdaqGS:AVXL) Q4 2025 Earnings Call November 25, 2025 08:30 AM ET Company ParticipantsSandra Boenisch - Principal Financial OfficerChristopher Missling - President and CEONone - Company RepresentativeConference Call ParticipantsJesse Silvera - AnalystTom Bishop - AnalystOperatorI'll be your host for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and during this session, if you would like to ask a question, ...

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has ...

TOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has completed the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector (SC-AI), LEQEMBI IQLI ...

Novo Nordisk reported results Monday for its trial to determine whether the active ingredient in Ozempic and Wegovy could slow the progression of Alzheimer's. Sergei Gapon / AFP / Getty Images Close Key Takeaways Novo Nordisk (NVO) shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial. The company had been looking to determine whether semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, could also slow the cognitive decline associated wit ...

Biogen Inc. (NASDAQ:BIIB) stock traded higher after Novo Nordisk A/S (NYSE:NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease.BIIB is reaching significant price levels. Watch the momentum hereThe trials did not confirm the superiority of semaglutide versus placebo in the reduction of progression of Alzheimer's disease, as measured by the change in Clinical Dementia Rating – Sum of Boxes (CDR-SB) score ...

Shares of Danish pharma major Novo Nordisk's plummeted a record 12.4% on 24 November — it's lowest since July 2021, after the company's popular weight-loss pill Ozempic failed trials for Alzheimer's treatment, Bloomberg reported.Novo Nordisk has discontinued its planned one-year extension for the pair of studies that were testing the drug's effectiveness in slowing the progression of Alzheimer's disease, it added.The two trials, with 3,500 participants with mild Alzheimer’s disease, had a 75% probability of ...

Shares in Novo Nordisk, the Danish firm best known for its Wegovy and Ozempic weight loss drugs, have plunged after it called a halt to closely-watched trials on a treatment for Alzheimer's disease.The company had been testing whether a key ingredient in the drugs could slow progression of the brain disorder. Novo Nordisk, which began the trials two years ago, had always treated the study as an outside bet but one which had the potential to land big rewards, if successful, as earnings from its core diabetes ...

Core Insights - Shares of Novo Nordisk fell by as much as 11% following the announcement that a trial for Alzheimer's disease did not meet its primary objective [1] Group 1: Company Performance - The trial evaluated the effectiveness of semaglutide, the active ingredient in Novo's successful diabetes and weight loss medications Ozempic and Wegovy, in slowing the progression of Alzheimer's disease [1]

Core Insights - Novo Nordisk announced top-line results from the phase 3 evoke and evoke+ trials for oral semaglutide in early-stage symptomatic Alzheimer's disease, involving 3,808 adults [1][2] - The trials did not show superiority of semaglutide over placebo in slowing Alzheimer's disease progression, despite improvements in biomarkers [2][4] - The decision to explore semaglutide for Alzheimer's was based on real-world evidence and previous studies, although the likelihood of success was considered low [4] Study Details - The evoke and evoke+ trials were randomized, double-blind, and placebo-controlled, focusing on patients aged 55-85 with mild cognitive impairment or mild dementia due to Alzheimer's [3][7] - Semaglutide was administered at a dose of 14 mg once daily, with a total of 1,855 and 1,953 participants randomized in the two trials respectively [7] - The primary measure of efficacy was the change in Clinical Dementia Rating – Sum of Boxes (CDR-SB) score from baseline to week 104 [6][7] Safety and Tolerability - Semaglutide demonstrated a safe and well-tolerated profile consistent with previous trials, with over 37 million patient-years of exposure across various populations [3][4] - The one-year extension period of the trials will be discontinued due to the lack of efficacy observed [4] Future Presentations - Topline results will be presented at the Clinical Trials in Alzheimer's Disease (CTAD) conference on December 3, 2025, with full results to follow at the 2026 Alzheimer's and Parkinson's Diseases Conferences in March 2026 [4]